EIGR - セラドン (Eiger BioPharmaceuticals Inc.) セラドン

 EIGRのチャート


 EIGRの企業情報

symbol EIGR
会社名 Eiger BioPharmaceuticals Inc (セラドン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Eiger BioPharmaceuticals Inc. formerly Celladon Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV) exendin (9-39) for severe hypoglycemia and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara Turkey) LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.   セラドンは心臓血管疾患の遺伝子治療の開発に焦点を置く米国のバイオ医薬品会社。筋小胞体カルシウムATPア―ゼ(SERCA2:細胞内のカルシウムを制御する酵素)をタ―ゲットした心不全の治療薬「MYDICAR」の治験を行う。また、糖尿病や神経変性疾患に対するSERCA2の開発を行う。   Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis.
本社所在地 2155 Park Boulevard Palo Alto CA 94306 USA
代表者氏名 David A Cory デビッド・ア・コーリー
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 650-279-9845
設立年月日 36861
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 16人
url www.celladon.com
nasdaq_url https://www.nasdaq.com/symbol/eigr
adr_tso
EBITDA EBITDA(百万ドル) -37.52800
終値(lastsale) 11.2
時価総額(marketcap) 159535846.4
時価総額 時価総額(百万ドル) 158.39630
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 105.17830
当期純利益 当期純利益(百万ドル) -38.80900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Eiger Biopharmaceuticals Inc revenues was not reported. Net loss decreased 16% to $18.7M. Lower net loss reflects Research and development - Balancing val decrease of 27% to $11.1M (expense) Stock-based Compensation in SGA decrease of 14% to $1.5M (expense) Interest Income increase of 27% to $283K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.68 to -$1.66.

 EIGRのテクニカル分析


 EIGRのニュース

   Eiger BioPharmaceuticals Inc Shares Fall 3.1% Below Previous 52-Week Low - Market Mover  2022/01/14 06:14:08 Kwhen Finance
Eiger BioPharmaceuticals Inc (EIGR) shares closed 3.1% lower than its previous 52 week low, giving the company a market cap of $155M. The stock is currently down 11.6% year-to-date, down 59.5% over the past 12 months, and down 60.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 47.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -559.7% The company's stock price performance over the past 12 months lags the peer average by 295.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Eiger BioPharmaceuticals Inc Shares Close in on 52-Week Low - Market Mover  2022/01/11 01:53:58 Kwhen Finance
Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 1.5% above its 52 week low of $4.78, giving the company a market cap of $165M. The stock is currently down 6.0% year-to-date, down 58.2% over the past 12 months, and down 58.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 43.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -422.9% The company's stock price performance over the past 12 months lags the peer average by 313.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Eiger BioPharmaceuticals Inc Shares Approach 52-Week Low - Market Mover  2022/01/07 02:44:59 Kwhen Finance
Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 0.6% above its 52 week low of $4.95, giving the company a market cap of $169M. The stock is currently down 4.0% year-to-date, down 60.4% over the past 12 months, and down 57.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 47.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -332.2% The company's stock price performance over the past 12 months lags the peer average by 399.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Eiger BioPharmaceuticals Inc Shares Near 52-Week Low - Market Mover  2021/12/30 01:30:23 Kwhen Finance
Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 1.0% above its 52 week low of $5.07, giving the company a market cap of $175M. The stock is currently down 57.9% year-to-date, down 50.1% over the past 12 months, and down 52.8% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 14.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 291.2% The company's stock price performance over the past 12 months lags the peer average by 209.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection  2021/12/21 21:05:00 Business Insider Markets
PALO ALTO, Calif., Dec. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious
   Caxton Corp Buys Rezolute Inc, Addex Therapeutics, Lux Health Tech Acquisition Corp, Sells ...  2021/08/24 18:38:06 GuruFocus
Related Stocks: GOOG , INTU , PYPL , CDLX , FB , EIGR , RZLT , ADXN , LUXA , FLAC , SSAAU , GIGGU , MRAC , PTMN , GMIIU , FTOC , HEC , VGAC ,
   Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2021 Results - Earnings Call Transcript  2021/08/08 13:37:04 Seeking Alpha
   thoughts on these estimates, before EPS results? NASDAQ:KDMN, NASDAQ:EIGR, NASDAQ:SLRX, NASDAQ:FGBI  2021/08/07 23:25:00 Stock Market Daily
Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis The post thoughts on these estimates, before EPS results? NASDAQ:KDMN, NASDAQ:EIGR, NASDAQ:SLRX, NASDAQ:FGBI appeared first on .
   Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism  2021/08/05 12:00:00 PR Newswire
PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food
   Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences  2021/08/03 20:05:00 PR Newswire
PALO ALTO, Calif., Aug. 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory,
   Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021  2021/05/26 00:00:00 BioSpace
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Healthcare Conference
   Eiger BioPharmaceuticals (NASDAQ:EIGR) Price Target Raised to $26.00 at Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell  2021/05/12 09:14:57 Transcript Daily
Eiger BioPharmaceuticals (NASDAQ:EIGR) had its target price boosted by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell from $23.00 to $26.00 in a report issued on Tuesday, Stock Target Advisor reports. Several other equities research analysts also recently weighed in on EIGR. Citigroup boosted their target price on shares of Eiger BioPharmaceuticals from []
   Eiger BioPharmaceuticals Inc. Shares Close the Day 11.4% Higher - Daily Wrap  2021/02/08 22:30:00 Kwhen Finance
Eiger BioPharmaceuticals Inc. shares closed today 11.4% higher than it did at the end of yesterday. The stock is currently down 11.4% year-to-date, down 7.9% over the past 12 months, and up 881.1% over the past five years. Today, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.7%. Trading Activity Shares traded as high as $12.25 and as low as $9.92 this week.Shares closed 9% below its 52-week high and 1e+2% above its 52-week low.Trading volume this week was 6.6% lower than the 10-day average and 34.6% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date lags the peer average by -116.3% The company's stock price performance over the past 12 months lags the peer average by -106.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Eiger BioPharmaceuticals Inc. Shares Close the Week 17.4% Higher - Weekly Wrap  2020/12/11 22:30:00 Kwhen Finance
Eiger BioPharmaceuticals Inc. shares closed the week 17.4% higher than it did at the end of last week. The stock is currently down 31.1% year-to-date, down 21.6% over the past 12 months, and up 715.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $10.48 and as low as $8.61 this week. Trading volume this week was 177.7% higher than the 10-day average and 131.0% higher than the 30-day average. Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. MACD, a trend-following momentum indicator, indicates an upward trend. The stock closed below its Bollinger band, indicating it may be oversold. The stock closed at Infinity% higher than its 5-day moving average, 6.9% higher than its 20-day moving average, and 3.4% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's price-earnings ratio is the same as its average peer. The company's performance over the last 1 year lags its average peer by -122.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セラドン EIGR Eiger BioPharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)